trial

Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia

NCTId NCT01163227
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 57 (actual)
Sponsored by Novartis Pharmaceuticals
Primary completion 2011-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
57 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Double
Start
2010-05
Primary completion
2011-09
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
AQW051 2 mg (single and multiple doses)AQW051 15mg (single and multiple doses)AQW051 100mg (single dose), and 50mg (multiple doses)

Sponsors

Novartis PharmaceuticalsLead Sponsor

Sites

2 total
Glendale, United StatesWillingboro, United States

Linked catalysts

1
Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophr — primary completion2011-09

Facts & assertions

4 sourced
Enrollment
57
Phase
PHASE2
Primary Completion Date
2011-09
Status
COMPLETED
relationships
The graph out of here
drug
AQW051 2 mg (single and multiple doses)
drug
AQW051 15mg (single and multiple doses)
drug
AQW051 100mg (single dose), and 50mg (multiple doses)
drug
lead_sponsor
Novartis Pharmaceuticals
company
indication
Hallucinations
indication
Delusions
indication
Schizophrenia Disorders
indication